In this edition of Amati Insights, Mikhail Zverev and Graeme Bencke discuss the key themes emerging from two major pharmaceutical industry conferences: CPHI and the Festival of Biologics.

The conversation explores how artificial intelligence is transforming drug discovery by helping researchers identify promising drug candidates more quickly and efficiently. As AI expands the number of molecules entering development, demand is also increasing for laboratory automation, clinical trial services and life sciences tools that support the testing and scaling of new treatments.

Mikhail and Graeme also examine the continued shift towards biologic medicines, including antibody therapies, radiopharmaceuticals, cell therapies and gene therapies. These advances are driving greater complexity in drug manufacturing and creating opportunities for companies involved in bioprocessing, laboratory technologies and healthcare automation.

The discussion further considers the growing importance of pharmaceutical logistics, supply-chain resilience and specialised distribution networks as biologic therapies become a larger part of global healthcare markets.

Watch the latest Amati Insights call as Mikhail and Graeme share their latest thinking on healthcare innovation, the accelerating impact of AI across the pharmaceutical industry, and the long-term investment opportunities they see emerging throughout the life sciences ecosystem.